TMBIM6 and prostate carcinoma: BI-1 has been reported to act as an important anti-tumor protein, which is upregulated in lung cancer [38,39], breast cancer [40,41], prostate cancer [24], and nasopharyngeal cancer [22,23], whereas downregulation of BI-1 induces cancer cell death in both prostate cancer and nasopharyngeal cancer [22,23,24].